美股异动 | Moderna(MRNA.US)涨超7% 两款新mRNA疫苗数据积极

Core Viewpoint - Moderna's stock price increased by over 7% to $27.85 following the presentation of new data on its mRNA vaccine pipeline at the IDWeek 2025 conference, indicating positive market reaction to the clinical results of its seasonal flu vaccines [1] Group 1: Vaccine Data Presentation - Moderna showcased the latest clinical results for its mRNA-1010 seasonal flu vaccine and the mRNA-1018 combination vaccine at the IDWeek 2025 conference [1] - The data revealed that both vaccines elicited rapid and robust immune responses in adult participants [1] - No significant safety issues were observed during the clinical trials for these vaccines [1]